Tuesday, November 24, 2020

WHO advises against remdesivir for Covid-19 treatment

WHO says there is 'no evidence based on currently available data that it does improve patient-important outcomes'.

Other News

Bekas menteri bidas pengeluar sarung tangan Top Glove selepas lebih 1,000 pekerja dijangkiti Covid-19

Syed Saddiq Syed Abdul Rahman mengatakan syarikat itu perlu dikenakan ‘cukai durian runtuh’ kerana keuntungan luar biasa mereka.

Ex-minister slams Top Glove after over 1,000 workers down with Covid-19

Syed Saddiq Syed Abdul Rahman says a 'windfall tax' should be imposed on Top Glove due to its unusual profits.

1,884 kes baru Covid-19, Selangor tertinggi

Sebanyak 883 pesakit pulih.

Record 1,884 new cases, 1,203 in Selangor

Two more deaths take toll to 337.

EC planning for possible election during post Covid-19 period

Law minister Takiyuddin Hassan says the EC has drafted a set of guidelines for the event of an election during this time.

The anti-viral drug remdesivir should not be used to treat Covid-19 patients no matter how severe their illness as it has “no important effect” on survival chances, the World Health Organization (WHO) said Friday.

Scratching one of the few treatments that had shown some initial promise in severe patients, a WHO Guideline Development Group (GDG) of international experts said there was “no evidence based on currently available data that it does improve patient-important outcomes”.

The US, the European Union and other countries have granted temporary approval for the use of remdesivir after initial research showed it may shorten recovery time in some coronavirus patients.

President Donald Trump was treated with remdesivir among other medicines after he tested positive for Covid-19 in October.

Friday’s WHO recommendation was based on four international randomised trials among more than 7,000 patients hospitalised with the virus.

Publishing updated treatment guidance in the BMJ medical journal, the panel acknowledged that their recommendation does not mean that remdesivir has no benefit for patients.

But based on the latest figures, costs and delivery methods, it advised “against administering remdesivir in addition to usual care for the treatment of patients hospitalised with Covid-19, regardless of disease severity”.

Manufacturer Gilead said last month that the drug had boosted 2020 third quarter sales by almost US$900 million.

Initially developed as a treatment for the Ebola virus, remdesivir was found in one study published in May to reduce the length of hospital stays for Covid-19 sufferers from 15 to 11 days on average.

A subsequent WHO pre-print however found the drug “appeared to have little or no effect” on mortality or length of hospitalisation among more than 11,000 hospitalised patients across 30 countries.

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

Ex-minister slams Top Glove after over 1,000 workers down with Covid-19

Syed Saddiq Syed Abdul Rahman says a 'windfall tax' should be imposed on Top Glove due to its unusual profits.

Record 1,884 new cases, 1,203 in Selangor

Two more deaths take toll to 337.

AstraZeneca, Oxford say Covid vaccine shows 70% efficacy

The 70% average is lower compared with the efficacy of coronavirus vaccines trialled by rivals Pfizer/BioNTech and Moderna which have come in above 90%.

Toronto enters virus lockdown as US looks to vaccine rollout

Toronto has banned private indoor gatherings and capped the size of weddings and funerals for four weeks.

South Korea gets aggressive with third wave ‘in full swing’

'We’re at a critical juncture of facing a large number of infections nationwide.'